In colorectal cancer (CRC), where early detection significantly improves outcomes, CRISPR‐Cas9 shows promise in identifying key gene mutations (e.g., PIC3C3A, KRAS, TP53, SMAD4, APC) in CRC organoids and detecting de novo driver genes. The gene discussed is SMAD4; the disease is colorectal carcinoma.